
Cookie Recall Update For 15 States as FDA Issues Risk Level
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A food recall of nearly 6,000 cases of cookies distributed across 15 states has been given the U.S. Food and Drug Administration's (FDA) second-highest risk level.
Carley's Inc. voluntarily recalled 5,826 cases of its Soft Baked Iced Lemon Cookies, which contained a misbranded yellow color additive, which was incorrectly labeled "Artificial Yellow Color" instead of the regulatory "FD&C Yellow #5" (or Tartrazine), the FDA said.
The agency on Wednesday classified the recall a Class II, reserved for situations in which a product may cause temporary or medically reversible adverse health issues or there is a remote probability of serious adverse health consequences.
The cookies were shipped to wholesalers in the following states: Illinois, Michigan, Iowa, Louisiana, Maryland, Pennsylvania, Virginia, Minnesota, Alabama, Texas, Georgia, South Carolina, New York, North Carolina, and West Virginia.
Newsweek contacted Carley's via its information email on Thursday.
What To Know
The recalled product, Carley's Soft Baked Iced Lemon Cookies (5.34oz plastic tray), bears UPC code 7 40235 50011 0 and various lot codes including 01726-040225, 11245-012825, 031026-051425, 061925-082324, 080525-100924, 081725-102124, 091025-111424, and 112425-012825. Carley's shipped 5,826 cases (nearly 70,000 units) to wholesalers who then distributed them to retail stores in 15 states.
The recall was initiated on June 6. Carley's Inc. notified its customers and wholesalers using a combination of email, fax, letter, press release, telephone, and personal visits. No initial press release was formally issued for this recall.
Stock photo shows homemade cookies.
Stock photo shows homemade cookies.
Getty Images
The FDA requires specific identification of food color additives due to potential sensitivities. FD&C Yellow #5 (also known as tartrazine) has been associated with rare allergic-type reactions, particularly among individuals with aspirin sensitivity.
FD&C Yellow No. 5 is approved by the U.S. Food and Drug Administration (FDA) for use in foods, drugs, and cosmetics. It must be listed on ingredient labels because some people may have allergic reactions or sensitivities.
No U.S. state outright bans FD&C Yellow No. 5, but there have been increasing regulatory and labeling efforts around artificial food dyes, particularly in states like California and New York.
The FDA's Recall Levels Explained
Recalls are classified into a numerical designation (I, II, or III) by the FDA to indicate the relative degree of health hazard presented. The categories are:
Class I - a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.
Class II - a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Class III - a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
What Happens Next
The voluntary recall remains ongoing.
The recall will remain active until the FDA and Carley's Inc. have resolved the labeling issue and ensured that all misbranded products are removed from the market. Consumers who have purchased affected cookies should return them for a full refund, and can monitor the FDA recall database for updates.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Business Insider
11 hours ago
- Business Insider
Cofounder of Neuralink rival Precision Neuroscience reveals what people often get wrong about brain implants
At least that's the line from Dr. Ben Rapoport, the cofounder and chief science officer of Precision Neuroscience, a brain-computer interface, or BCI, company. "Many people have the impression that the data that we care about is sort of everywhere inside this dimensional structure," Rapoport, a neurosurgeon and engineer, told Business Insider. That's a big misconception, he said. People often incorrectly assume that "you need electrodes that penetrate deep inside the brain to get that information out," he added. But brain implants don't need to be as invasive as they might sound, he said. Precision is developing a thin film that sits on the brain and records brain activity in patients with paralysis. "We implant modules of 1,024 electrodes on the brain surface in the area that controls movement, especially the hand," Rapoport said. That allows them to have cursor control, typing ability, access the internet, use PowerPoint, play games, and word process, he added. These are actions that require vision, movement, sensation, and executive function — core parts of consciousness that are concentrated in the brain's outermost layer, the cortex, Rapoport said. Deeper inside are "connections, you know, between those activities and also sort of subconscious processes, because the brain coordinates a lot of activities in the body that don't take place consciously," he added. The New York-based startup, which received FDA clearance for part of its wireless brain-computer interface in April, has raised $155 million in funding since it launched in 2021. It is one of a few companies advancing this technology as part of the Implantable BCI Collaborative Community. BCIs are largely classified into two categories: invasive and non-invasive. Non-invasive BCIs, which don't require surgery, often rely on external sensors to detect the electrical signals in the brain. BCS that are implanted record neural activity directly from the brain and are being developed to restore speech, movement, and other complex functions in people with neurological conditions. The buzziest BCI these days is Elon Musk's Neuralink, which has ambitions to create a "symbiosis" between the human brain and AI. But there are a host of other companies working on BCIs as a way to treat neurological diseases, like Precision Neuroscience. The company has tested its temporary device in over forty patients in early clinical studies. Over the next year, it will prepare for the first human studies of its permanently implanted devices. "There are certain internal validation checks and internal milestones that we need to meet for ourselves and for the FDA before we want to start implanting the permanently implanted wireless device in humans," Rapoport said. The company's ultimate goal is to help paralyzed people get "back to a level of functional capacity where they can be significantly independent, economically self-sufficient, and hold a job in the workplace," Rapoport said. Correction: June 27, 2025 — An earlier version of this story said that Dr. Ben Rapoport was the founder and CEO of Precision Neuroscience; Dr. Rapoport is the cofounder and chief science officer. An earlier version also mischaracterized the film that goes on the brain. It is not studded with electrodes; the electrodes are embedded.